HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 42 cents in second-quarter fiscal 2021, which beat the Zacks Consensus Estimate of 27 cents by 55.6%. The bottom line fell 4.5% on a year-over-year basis.
Revenues in Detail
Thecompany generated revenues of $176 million, beating the Zacks Consensus Estimate by 2.7%. However, the figure skyrocketed 103% from the prior-year quarter.
HSA Member Detail
As of Jul 31, 2020, the total number of Health Savings Accounts (HSA), for which HealthEquity served as a non-bank custodian (HSA members), was 5.4 million, up 29% year over year.
Additionally, total Active HSA assets were $12.2 billion, up 43% year over year.
Total Accounts, including HSAs and complementary CDB accounts, came in at 12.5 million, up 158% year over year.
Service Revenues: At this segment, revenues totaled $103.8 million, up 294.7% from the year-ago figure.
Custodial Revenues: At this segment, revenues grew 7.6% year over year to $46.9 million.
Interchange Revenues: At this segment, revenues soared 51.4% year over year to $25.3 million.
HealthEquity, Inc. Price, Consensus and EPS Surprise
HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote
HealthEquity generated gross profit of $101.8 million, up 74.2% from the year-ago quarter. Gross margin was 57.8% of net revenues, down 965 basis points (bps) year over year.
Adjusted operating profit in the fiscal second quarter was $50.6 million, up 34.9% year over year. Adjusted operating margin totaled 28.8% in the quarter, contracting 1456 bps year over year.
The company exited the fiscal second quarter with cash and cash equivalents of $268.9 million, compared with $720.8 million at the end of the fiscal first quarter.
Cumulative cash flow from operating activities in the second quarter came in at $68.7 million, up from $56.8 million in the year-ago period.
For fiscal 2021, revenues are projected within $720 million and $730 million. The Zacks Consensus Estimate for the same is pegged at $738.6 million.
Adjusted earnings per share are expected within $1.48 and $1.58. The Zacks Consensus Estimate for the same is pegged at $1.44.
HealthEquity exited second-quarter of fiscal 2021 on a strong note.The company witnessed strong growth in Service, Custodial and Interchange segments.Notably, solid growth in HSAs and custodial assets bolstered the top line. In addition to HSA, the company offers health reimbursement arrangement and health flexible spending account to regional employers. HealthEquity accelerated its integration efforts (WageWorks buyout that closed on Aug 30, 2019) and achieved the previously-announced goal of $50 million in run rate synergies, including the on-shoring of all telephone-based member services to the United States, by the end of the fiscal second quarter.
However, a significant drop in adjusted operating and gross margin raises concern. The company also faces stiff competition in the Medical Services market. HealthEquity is required to comply with the strict treasury regulations formulated by the Internal Revenue Service (IRS).
Zacks Rank and Other Key Picks
HealthEquity currently carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. TMO, PerkinElmer, Inc. PKI and OPKO Health, Inc. OPK. While PerkinElmer sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PerkinElmer, Inc. (PKI) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.